Document Detail

Potassium magnesium supplementation for four weeks improves small distal artery compliance and reduces blood pressure in patients with essential hypertension.
MedLine Citation:
PMID:  16820345     Owner:  NLM     Status:  MEDLINE    
It has been postulated that the loss of arterial compliance may precede cardiovascular diseases, and that arterial compliance is an important parameter to consider when evaluating arterial diseases such as essential hypertension (EH) and the effects of antihypertensive treatment. In all, 133 EH patients and 147 healthy subjects were enrolled in this study. Large arterial compliance (C1) and small arterial compliance (C2) were measured by the CVProfilor DO-2020 CardioVascular Profiling System. Thirty-five patients randomly received magnesium potassium supplementation (magnesium, 70.8 mg/d; potassium, 217.2 mg/d) for four weeks, and 32 patients received lacidipin (4 mg/d) as a control. Before and after the four weeks, blood pressure, C1, and C2 were measured. It was found that arterial compliance was significantly lower in EH patients compared with healthy subjects (C1: 12.53 +/- 0.33 vs. 15.63 +/- 0.30 ml/mmHg x 10, p < 0.01;C2: 3.79 +/- 0.17 vs. 5.69 +/- 0.25 ml/mmHg x 100, p < 0.01). On lacidipine, systolic and diastolic BP decreased 13.27 +/- 1.76 mm Hg and 6.33 +/- 1.55 mm Hg, and C1 and C2 compliance values increased 25.05% +/- 4.49% and 34.50% +/- 7.40%, respectively. On K+ and Mg2+ supplementation, systolic and diastolic BP decreased 7.83 +/- 1.87 mm Hg and 3.67 +/- 1.03 mm Hg, and C1 and C2 compliance values increased 12.44% +/- 4.43% and 45.25% +/- 6.67%, respectively. Decreases in systemic vascular resistance (mean arterial pressure divided by cardiac output) by 11.9% and 16.6 % (p < 0.01) were seen between the drug-induced changes, respectively. Both large arterial compliance and small arterial compliance were decreased in essential hypertension patients. In essential hypertension patients, magnesium and potassium supplementation could improve small arterial compliance, while lacidipine improved large arterial compliance significantly.
Geru Wu; Hongyan Tian; Ke Han; Yutao Xi; Yan Yao; Aiqun Ma
Related Documents :
7134805 - Evidence of increased peripheral catecholamine release in patients with long-standing, ...
24580615 - Novel high-pressure monoclinic metallic phase of v2o3.
9002295 - Autonomic nervous system functions in childhood essential hypertension.
6681025 - Adrenal and sympathetic nervous activity in subjects with "low' and "high' normal blood...
22018525 - The cardiac cycle is a major contributor to variability in size measurements of abdomin...
9798115 - Adiposity and blood pressure in a multiethnic population of women in hawaii.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Clinical and experimental hypertension (New York, N.Y. : 1993)     Volume:  28     ISSN:  1064-1963     ISO Abbreviation:  Clin. Exp. Hypertens.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-07-05     Completed Date:  2006-12-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9305929     Medline TA:  Clin Exp Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  489-97     Citation Subset:  IM    
Cardiovascular Department, the First Hospital of Xi'an Jiaotong University, Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use
Arteries / drug effects*,  physiopathology
Biological Markers / blood
Blood Pressure / drug effects*
Case-Control Studies
Dietary Supplements*
Dihydropyridines / therapeutic use
Follow-Up Studies
Hypertension / blood,  diet therapy*,  drug therapy,  physiopathology*
Magnesium / administration & dosage*
Middle Aged
Multivariate Analysis
Potassium, Dietary / administration & dosage*
Time Factors
Treatment Outcome
Vascular Resistance / drug effects*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biological Markers; 0/Dihydropyridines; 0/Potassium, Dietary; 103890-78-4/lacidipine; 7439-95-4/Magnesium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatril...
Next Document:  Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.